The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

被引：40

作者：

Rampa, Angela ^{[1
]}

Bartolini, Manuela ^{[1
]}

Bisi, Alessandra ^{[1
]}

Belluti, Federica ^{[1
]}

Gobbi, Silvia ^{[1
]}

Andrisano, Vincenza ^{[1
]}

Ligresti, Alessia ^{[2
]}

Di Marzo, Vincenzo ^{[2
]}

机构：

[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy

[2] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

关键词：

Alzheimer's disease; drug design; FAAH; AChE; BuChE; carbamate inhibitors; ACID AMIDE HYDROLASE; ACETYLCHOLINESTERASE INHIBITORS; BRAIN; NEUROTOXICITY; CARBAMYLATION; DERIVATIVES; MECHANISM; LIGANDS; SYSTEM; TARGET;

D O I：

10.1021/ml200313p

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The treatment of Alzheimer's disease (AD) still remains an area of significant unmet need, with drugs that only target the symptoms of the disease. Therefore, there is considerable need for disease-modifying therapies. The complex etiology of AD prompts scientists to develop multitarget strategies to combat causes and symptoms. To this aim, we designed, synthesized, and tested four new carbamates as dual cholinesterase-FAAH inhibitors. The dual activity of these compounds could lead to a potentially more effective treatment for the counteraction of AD progression, because they would allow regulation of both ACh and eCB signaling and improve neuronal transmission and/or counteract neuroinflammation.

引用

页码：182 / 186

页数：5

共 50 条

[11] The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj, Shivanshu
Jain, Shreshta
Vyas, Preeti
Bawa, Sandhya
Vohora, Divya
BRAIN RESEARCH BULLETIN, 2021, 174 : 305 - 322
[12] Role of the endocannabinoid system in Alzheimer's disease:: New perspectives
Pazos, MR
Núñez, E
Benito, C
Tolón, RM
Romero, J
LIFE SCIENCES, 2004, 75 (16) : 1907 - 1915
[13] Epidemiology of Alzheimer's disease: methodological approaches and new perspectives
Berr, Claudine
Vercambre, Marie-Noel
Akbaraly, Tasnime Nassime
PSYCHOLOGIE & NEUROPSYCHIATRIE DU VIEILLISSEMENT, 2009, 7 : 7 - 14
[14] Treatment of Alzheimer's disease: current status and new perspectives
Scarpini, E
Scheltens, P
Feldman, H
LANCET NEUROLOGY, 2003, 2 (09): : 539 - 547
[15] Pharmacological mTOR inhibitors in ameliorating Alzheimer's disease: current review and perspectives
Xie, Pei-Lun
Zheng, Meng-Yu
Han, Ran
Chen, Wei-Xin
Mao, Jin-Hua
FRONTIERS IN PHARMACOLOGY, 2024, 15
[16] Proven Therapies and new Perspectives for the Management of Alzheimer's Disease
Ameri, Abdol A.
NERVENHEILKUNDE, 2011, 30 (12) : 1013 - 1016
[17] Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimer's Disease
Campillo, N. E.
Paez, J. A.
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 539 - 559
[18] Muscarinic Receptors and Alzheimer's Disease: New Perspectives and Mechanisms
Monaco, Martina
Trebesova, Hanna
Grilli, Massimo
CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 6820 - 6835
[19] In silico study of selected alkaloids as dual inhibitors of β- and γ-secretases for Alzheimer's disease
Onifade, Isreal Ayobami
Umar, Haruna Isiyaku
Aborode, Abdullahi Tunde
Awaji, Aeshah A.
Jegede, Ifeoluwapo Deborah
Adeleye, Bunmi Helen
Fatoba, Dorcas Oladayo
Bello, Ridwan Opeyemi
Fakorede, Sodiq
Idowu, Nike
JOURNAL OF ALZHEIMERS DISEASE, 2025, 103 (04) : 1191 - 1215
[20] Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer's disease
Velueta-Viveros, Martha
Martinez-Bailen, Macarena
Puerta, Adrian
Romero-Hernandez, Laura L.
Kren, Vladimir
Merino-Montiel, Penelope
Montiel-Smith, Sara
Fernandes, Miguel X.
Moreno-Vargas, Antonio J.
Padron, Jose M.
Lopez, Oscar
Fernandez-Bolanos, Jose G.
BIOORGANIC CHEMISTRY, 2022, 127

← 1 2 3 4 5 →